Decision Resources, Inc., announces the publication of Allergic Rhinitis, a new study that assesses promising therapies and their projected impact on the allergic rhinitis (AR) market over a 1999-2009 forecast period. AR affects nearly 150 million people in the world's seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan), making this disease a highly attractive target for pharmaceutical companies. The U.S. market is especially lucrative, with sales of prescription drugs for AR estimated at $3.7 billion in 1999 (80% of total sales for all seven markets). The phenomenal U.S. sales of the blockbuster antihistamine loratadine (Schering- Plough's Claritin), which exceeded $1.7 billion for AR in 1999, merely serves to illustrate the tremendous market potential for successful drugs in this sector. Furthermore, allergy experts estimate that only 30-45% of AR patients are actually diagnosed with the condition by a physician. Consequently, there is a vast population of AR sufferers who could benefit from prescription medications that are either more potent or produce fewer side effects than available over-the-counter (OTC) drugs.
Two of the most advanced agents in clinical trials for AR received approval in Europe in January 2001: Schering-Plough's desloratadine and UCB's levocetirizine. Following European approval, desloratadine was also approved in the United States. These new third-generation antihistamines -- along with Sepracor's norastemizole, which is in Phase III trials in the United States -- are expected to offer fewer side-effects and/or increased potency over their predecessors (loratadine, cetirizine, and astemizole).
Sales of prescription drugs to treat AR in the seven major pharmaceutical markets are expected to surpass $5.6 billion by 2009. The chief factors fueling this growth will be increases in the diagnosed population across all markets as the public becomes more aware of prescription drug treatments and the introduction of more potent (and expensive) therapies to treat the more severe cases of AR. Despite the fact that the newer therapies (i.e., antihistamine/antileukotriene combination agents and anti-IgE Mab therapy) are not expected to be prescribed for a large percentage of the patient population by 2009, these agents will garner substantial sales as a direct result of their expected higher price tags.
Allergic Rhinitis is part of the Immune and Inflammatory Disorders portfolio, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years.
Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or email@example.com (e-mail). In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or firstname.lastname@example.org (e-mail). In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or email@example.com (e-mail).
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 201-369-3467
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., 781-296-2553, or